Clinical features and management of erythromelalgia: long term follow-up of 46 cases.

نویسندگان

  • Louise K Parker
  • Cristina Ponte
  • Kevin J Howell
  • Voon H Ong
  • Christopher P Denton
  • Benjamin E Schreiber
چکیده

OBJECTIVES To review our clinical experience of this rare condition and describe the clinical features and response to therapy in a cohort of patients with erythromelalgia (EM), a rare condition, characterised by paroxysmal hyperthermia of the extremities with erythema, pain and intense burning. METHODS A review was made of the electronic and paper medical records of patients with the diagnosis of EM, with a telephone interview to verify and complete clinical information relating treatment and outcome. RESULTS 46 patients (41 females) were included in this study. Mean age was 57 years and mean duration of symptoms was 16 years. Raynaud's phenomenon was present in 36 patients (80%) and 4 patients (9%) had systemic sclerosis. Smoking (current or previous) was identified as a possible risk factor in 26 cases and exposure to chronic vibration in 3 cases. Overall, the effect on quality of life was mild in 15% of cases, moderate in 30% and severe in 48%. The most common symptoms were burning (96%), heat (93%), pain (87%), and redness (83%). Symptoms affected the lower limbs in 98% of cases, upper limbs in 76%, face in 20% and trunk in 11%. Triggers included heat (85%), exercise (78%) and time of day (76%). Various medications were tried, showing poor effect in most cases. Intravenous iloprost was given to 27 patients, with benefit in 17 patients (63%). CONCLUSIONS Erythromelalgia is a rare chronic debilitating condition. Exercise, heat and night time are common triggers. Current medical therapies are seldom effective and further research is sorely needed.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Keratolimbal Allograft in the Management of Delayed-Onset Mustard Gas Keratopathy: Long-term Results

Purpose: To evaluate the long-term results of Keratolimbal allograft (KLAL) in the management of Delayed-onset Mustard Gas Keratopathy (MGK). Methods: This cross-sectional descriptive study considers those patients with documented MGK, who underwent KLAL between 2002 and 2016 in the Department of ophthalmology, Labbafinejad Medical Center. After obtaining consent, the patients were followed clo...

متن کامل

Which complaint has the most clinical effect on quality of life of thyroid cancer survivors in long term follow up?

Introduction: Differentiated thyroid cancer (DTC) is the most common endocrine malignancy. This malignancy generally has an excellent prognosis with more than 90% long term survival. Consequently, life quality improvement is the first priority especially in the young DTC survivors. In classic management of a new DTC patient, each therapeutic modality can significantly induce morbidities. In the...

متن کامل

CLINICAL TRIAL OF TRICLABENDAZOLE ON HUMAN FASCIOLIASIS: LONG TERM FOLLOW UP

Following an outbreak: of human fascioliasis in Gilan province of Iran in 1989, the benzimidazole derivative triclabendazole (TCBZ) was suggested as the drug of choice after finding out that routine drugs were not effective. Two studies were performed: a clinical trial (before/after type) in 1989 and a historical cohort (1989- 1995) to examine the efficacy of the drug. TCBZ was administere...

متن کامل

نتایج درمان و بقا در کودکان مبتلا به لوسمی میلوئیدی حاد non APL مراجعه‌کننده به بیمارستان حضرت علی اصغر(ع) (1381-1366)

     Background & Aim: AML accounts for about 15% of all childhood leukemia. The improvement has been seen over the past decades after treating with chemotherapy alone. The outcome has been better for children and it has had long term survival for all patients treated with BFM protocol chemotherapy. The aim of the present study was to investigate long-term survival in patients referred to Ali A...

متن کامل

Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®

Factor XIII deficiency (FXIIID) is an extremely rare hemorrhagic disorder with a prevalence of 1/3-5 million. Management of disease is performed by fresh frozen plasma (FFP), Cryoprecipitate (CP) or FXIII concentrate (Fibrogammin P®). Our objective was to assess safety and effectiveness of Fibrogammin P® in patients with FXIIID. For this purpose we designed this long-term follow up study on a l...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Clinical and experimental rheumatology

دوره 35 1  شماره 

صفحات  -

تاریخ انتشار 2017